Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Assets Measured at Fair Value on Recurring Basis

The following table presents information about our assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

September 30, 2020	Level 1		Level 2		Level 3		Total
Assets
Cash	$	1,383	$	—	$	—	$	1,383
Money market securities (cash equivalents)		21,010		—		—		21,010
Restricted cash		50		—		—		50
Total assets	$	22,443	$	—	$	—	$	22,443

Summary of Cash and Cash Equivalents

Cash and cash equivalents consist of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
September 30, 2020	Cost		Gains		Losses		Fair Value
Cash	$	1,383	$	—	$	—	$	1,383
Money market securities		21,010		—		—		21,010
Total cash and cash equivalents	$	22,393	$	—	$	—	$	22,393
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50